Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03541564 · ClinicalTrials.gov registry record · Phase 1
An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants to Study Electrocardiogram Effects
A Phase 1 study of Healthy Participants and Systemic Lupus Erythematosus, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 84
- Enrollment target
- 1
- Study location
NCT03541564 is a Phase 1 study of Healthy Participants and Systemic Lupus Erythematosus that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 84 participants, above the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (29% higher). The trial reports 1 study location across 1 state.
The verdict
NCT03541564, a Phase 1 study of Healthy Participants and Systemic Lupus Erythematosus, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 84 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a study to investigate the experimental medication BMS-986165 in healthy participants in order to study the effects it has on electrocardiogram results.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Moxifloxacin
- DRUG BMS-986165
Study Locations (1)
Kansas
- PRA Health Sciences - Lenexa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2018-05-30 |
| Est. Completion | 2018-09-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03541564
The ClinicalTrials.gov registry entry for NCT03541564 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (29% higher). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Healthy Participants appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT03541564 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.
Frequently Asked Questions
What is clinical trial NCT03541564 about?
NCT03541564 is a clinical study titled "An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants to Study Electrocardiogram Effects". This is a study to investigate the experimental medication BMS-986165 in healthy participants in order to study the effects it has on electrocardiogram results.
What is the current status of trial NCT03541564?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 84 participants. The study started on 2018-05-30. Estimated completion is 2018-09-04.
What conditions does trial NCT03541564 study?
This clinical trial studies the following conditions: Healthy Participants, Systemic Lupus Erythematosus.
What interventions are being tested in trial NCT03541564?
The interventions under investigation include: Placebo (OTHER), Moxifloxacin (DRUG), BMS-986165 (DRUG).
Who is sponsoring clinical trial NCT03541564?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03541564 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Participants
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants
RECRUITING · Phase 1
-
Impact of Exogenous Ketones on Sleep and Breathing in Healthy Volunteers (K-SLEEP)
RECRUITING · Phase 1
-
A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food
RECRUITING · Phase 1
-
A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants
RECRUITING · Phase 1
-
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
RECRUITING · Phase 1
-
A Study to Learn About a Vaccine Against E Coli in Healthy Adults
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.